Stage 4S Neuroblastoma: What Are the Outcomes? A Systematic Review of Published Studies

Arimatias Raitio^{1,2} Michael J. Rice¹ Dhanya Mullassery¹ Paul D. Losty^{1,3}

¹ Department of Paediatric Surgery, Alder Hey Children's NHS Foundation Trust, Liverpool, Merseyside, United Kingdom

² Department of Paediatric Surgery, University of Turku, Turku, Finland

³ Institute of Translational Medicine, University of Liverpool, Liverpool, Merseyside, United Kingdom

Address for correspondence Paul D. Losty, MD, FRCS, FEBPS, Department of Paediatric Surgery, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, United Kingdom (e-mail: paul.losty@liverpool.ac.uk).

Eur J Pediatr Surg 2021;31:385–389.

Abstract

Introduction The prognosis of stage 4S/MS neuroblastoma has traditionally been reported as excellent, yet conflicting treatment protocols exist for this enigmatic disease. To critically address this question, we have undertaken a systematic review of published studies to accurately determine outcomes for infants with stage 4S/MS neuroblastoma.

Materials and Methods Studies were identified using MEDLINE, Embase, and Cochrane databases using the relevant search terms. Literature reviews, case reports, and adult studies were excluded. Data were extracted independently following article selection by three authors and reviewed by the senior author.

Results The original search retrieved 2,325 articles. Following application of exclusion criteria and removing duplicate data, 37 studies (1,105 patients) were included for final review. Overall patient survival was 84%. Twelve studies (544 patients) recorded MYCN status. Mortality in MYCN amplified tumors was 56%. Chromosome 1p/11q status was reported in four studies and 1p/11q deletion carried a 40% fatality rate. Management included observation only (201 patients, 8.5% mortality), surgical resection of primary tumor only (153 patients, 6.5% mortality), chemotherapy only (186 patients, 21% mortality), radiotherapy (5 deaths, 33% mortality), chemotherapy with surgery (160 patients, 10% mortality), surgery with radiotherapy (21 patients, 19% mortality), radiotherapy with chemotherapy (42 patients, 29% mortality), and surgery with chemotherapy and radiotherapy (27 patients, 33% mortality).

Conclusion There is a significant mortality observed in stage 4S/MS neuroblastoma infants with a dismal outcome observed in those patients with MYCN amplification and 1p/11q deletion. Those patients suitably amenable for conservative management or surgery to excise the primary tumor carry the best prognosis.

Keywords

- neuroblastoma
- INRG stage MS
- outcome
- stage 4S

received
June 29, 2020
accepted
August 16, 2020
published online
September 15, 2020

© 2020, Thieme. All rights reserved.
Georg Thieme Verlag KG,
Rüdigerstraße 14,
70469 Stuttgart, Germany

DOI <https://doi.org/10.1055/s-0040-1716836>.
ISSN 0939-7248.

Introduction

Stage 4S neuroblastoma was first described in 1971 by D'Angio et al and referred to very young patients with otherwise stage I or II disease, but with metastasis in the liver, skin, or bone marrow.¹ The International Neuroblastoma Risk Group (INRG) staging system has also reclassified 4S as stage MS and sets a patient age upper limit here at 18 months.^{2,3} Stage 4S neuroblastoma disease (MS stage) is typically characterized by an initial phase of rapid tumor progression followed by spontaneous regression in most cases.⁴ However, disease progression regardless of any therapy(s) deployed may be seen in only a minority of patients and survival rates reported in the literature varying range from 56 to 90% cases.^{5–9}

There is evidence that very young age at diagnosis (<2 months),^{10,11} life-threatening symptoms,¹² MYCN amplification,^{11,13} and chromosome 1p deletions¹³ are predictors of poor outcome in stage 4S neuroblastoma (stage MS). However, optimal treatment strategies and their outcomes still remain poorly understood.⁸

Against this background, the aim of this systematic review study was to accurately better define clinical outcomes of infants with stage 4S (stage MS) neuroblastoma taking into account the different treatment modalities employed with the biological features of this enigmatic neuroblastic tumor.

Materials and Methods

Identification and Selection of Studies

A comprehensive search of the published literature in MEDLINE, Embase, and Cochrane database(s) was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.¹⁴ Search was made using term “neuroblastoma” in combination with one of the following keywords: “4S” or “IVS” or “stage 4S” or “MS” or “stage IVS” or “infant” or “neonate” or “spontaneous regression” or “congenital.” All articles published up to May 15, 2020, were included in the review.

Inclusion and Exclusion Criteria

This study included all original articles reporting on outcomes of stage 4S (INRG stage MS) neuroblastoma. Non-English articles and case reports (<3 patients) were first excluded with title and abstract screening. Studies with no stage 4S patients and/or survival data were also excluded (→Fig. 1).

Data Extraction and Analysis

Identified articles were independently reviewed by three authors, and final selection was approved by the senior author. The data on the survival of patients with stage 4S (INRG stage MS) neuroblastoma were then extracted from the original publications. Data on the treatment modalities of stage 4S (INRG stage MS) neuroblastoma, MYCN, and chromosome 1p/11q deletion status were also included in the analyses where available.

Statistical Analysis

Chi-square and Fisher's exact tests were utilized to analyze categorical variables. A significance level of $p \leq 0.05$ (two-tailed) was set. Analyses were performed using JMP Pro, version 13.1.0 for Windows (SAS Institute Inc., Cary, North Carolina, United States).

Results

The original search through different databases retrieved 2,325 articles. A total of 1,623 studies were evaluated in screening of titles and abstracts after duplicates were excluded. Eighty-five articles met the inclusion criteria in screening and were selected for full-text review. After full-text review of 85 articles, 37 articles met the eligibility criteria and were selected for review (→Fig. 1). The published studies covered the time period(s) from 1971 to 2020.

In total, there were 1,105 patients with stage 4S (INRG stage MS) neuroblastoma identified with overall survival of 84%. The most common site of primary tumor location was the adrenal gland with metastasis observed in the liver. MYCN status was fully reported in 12 studies including 544 patients and MYCN amplification here carried 56% mortality. Chromosome 1p/11q deletions were only reported in three studies and 133 patients with 1p/11q deletion carried a 40% fatality rate (→Table 1).

A total of 201 patients were managed by observation only with an 8.5% mortality. Surgical resection of the primary tumor was performed on 153 patients with 6.5% fatality rate and surgery with chemotherapy on 160 patients with 10% mortality. The above-mentioned three treatment groups had significantly better outcome(s) compared with other treatment modalities listed ($p < 0.001$) (→Table 2). One hundred eighty-six patients were treated with chemotherapy only with 21% mortality.

Discussion

This systematic review demonstrates that stage 4S (INRG stage MS) neuroblastoma carries the best prognosis in only those groups of patients amenable for observation only or surgical resection of primary tumor with or without chemotherapy. Moreover, MYCN amplification and chromosome 1p/11q deletion were both predictors of mortality.

Observation only was the most commonly used treatment for stage 4S neuroblastoma. Spontaneous regression or differentiation to a ganglioneuroma phenotype is common in stage 4S (INRG stage MS) neuroblastoma with “benign” molecular biology.⁴ Here, most tumors can be treated with active observation only with modest outcome(s) anticipated including stage 4S (INRG stage MS) neuroblastoma mortality ranging from 0 to 19%.^{8,15–18}

Surgery with or without chemotherapy yielded excellent outcome(s) in stage 4S (INRG stage MS) neuroblastoma according to the quality of published literature reviewed here in this systematic review. Patients suitable for surgical resection of the offending primary tumor only had the best

Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses study selection flow diagram.

outcome(s).^{8,11,15,17} Those requiring neoadjuvant chemotherapy before definitive surgical resection had also good outcomes with only 10% mortality.^{11,15,19,20} Interestingly, those treated with surgical resection and radiotherapy with or without chemotherapy likely “scaled up” to control fulminant liver metastases had significantly worse outcome(s).

Patients with stage 4S (INRG stage MS) neuroblastoma treated with chemotherapy only had significant mortality compared with those treated with observation or surgery.

Chemotherapy only was the second most common treatment identified in this systematic review and reported mortality varied significantly ranging from 0 to 29%.^{8,11,17,21} We postulate that the inferior outcome(s) associated with chemotherapy are most likely reflective of the unfavorable anatomical site of tumor and/or their unique molecular tumor characteristics.²²

Radiotherapy alone was administered in 15 patients with 33% mortality (range: 0–100%).^{12,17,19,23} This review of

Table 1 Association of molecular biology and survival in 4S neuroblastoma

	Number of cases (n)	Deaths (n)	Mortality (%)	p-Value
MYCN amplification	36	20	55.6	<0.001
MYCN not amplified	498	53	10.6	
Chromosome 1p/11q deletion	10	4	40.0	0.02
Normal chromosome 1p/11q	123	11	8.9	

Table 2 Survival of stage 4S neuroblastoma with different treatment modalities

	Number of cases (n)	Deaths (n)	Mortality (%)
Observation	201	17	8.5
Surgery only	153	10	6.5
Surgery and chemotherapy	160	16	10.0
Chemotherapy only	186	39	21.0
Radiotherapy only	15	5	33.3
Surgery and radiotherapy	21	4	19.0
Radiotherapy and chemotherapy	42	12	28.6
Surgery, chemotherapy, and radiotherapy	27	9	33.3
Overall	1,105	174	15.7

published studies therefore shows that radiotherapy alone is associated with poor prognosis. Similarly, combination(s) of chemotherapy and radiotherapy were likewise associated with a significant fatality rate of 29%.^{1,11,12,17,23}

A lack of robust published data showing “evidence-based” selection criteria of deployed therapy strategies for patients with stage 4S (INRG stage MS) neuroblastoma is a main limitation of this current study. Fully comparing outcomes metrics of the varying molecular characteristics of the stage 4S (INRG stage MS) tumors between treatment groups were challenging due to limited information available. Finally, all included studies analyzed were retrospective cohort populations.

Conclusion

In conclusion, this study therefore demonstrates that stage 4S (INRG stage MS) neuroblastoma is associated with good outcome(s) in most cases. Molecular characteristics of the 4S (INRG stage MS) neuroblastic tumor are the best predictors of mortality. Those patients amenable for observation or surgical resection of primary tumor appear to have the best overall prognosis.

Conflict of Interest

Dr. Raitio reports grants from Emil Aaltonen Foundation and Turku University Foundation, outside the submitted work.

References

1 D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. *Lancet* 1971;1 (7708):1046–1049

2 Cohn SL, Pearson AD, London WBINRG Task Force, et al; The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. *J Clin Oncol* 2009;27(02):289–297

3 Monclair T, Brodeur GM, Ambros PFINRG Task Force, et al; The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. *J Clin Oncol* 2009;27(02):298–303

4 Brodeur GM. Spontaneous regression of neuroblastoma. *Cell Tissue Res* 2018;372(02):277–286

5 Koivusalo AI, Pakarinen MP, Rintala RJ, Saarinen-Pihkala UM. Surgical treatment of neuroblastoma: twenty-three years of

experience at a single institution. *Surg Today* 2014;44(03): 517–525

6 Moreno F, Lopez Marti J, Palladino M, Lobos P, Gualtieri A, Cacciavillano W. Childhood neuroblastoma: incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000–2012. *Pediatr Blood Cancer* 2016; 63(08):1362–1367

7 Youlden DR, Frazier AL, Gupta S, et al. Stage at diagnosis for childhood solid cancers in Australia: a population-based study. *Cancer Epidemiol* 2019;59:208–214

8 De Bernardi B, Di Cataldo A, Garaventa A, et al. Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry. *Ital J Pediatr* 2019;45(01):8

9 Salim A, Mullassery D, Pizer B, McDowell HP, Losty PD. Neuroblastoma: a 20-year experience in a UK regional centre. *Pediatr Blood Cancer* 2011;57(07):1254–1260

10 De Bernardi B, Pianca C, Boni Italian Cooperative Group on Neuroblastoma, et al; Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. *Cancer* 1992;70(06):1625–1633

11 Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience—a pediatric oncology group study. *J Clin Oncol* 1998;16(06):2007–2017

12 Hsu LL, Evans AE, D'Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. *Med Pediatr Oncol* 1996;27(06):521–528

13 Schleiermacher G, Rubie H, Hartmann ONeuroblastoma Study Group of the French Society of Paediatric Oncology, et al; Treatment of stage 4s neuroblastoma—report of 10 years' experience of the French Society of Paediatric Oncology (SFOP). *Br J Cancer* 2003;89(03):470–476

14 Moher D, Liberati A, Tetzlaff J, Altman DGPRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *BMJ* 2009;339:b2535

15 De Bernardi B, Gerrard M, Boni L, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. *J Clin Oncol* 2009;27(07): 1034–1040

16 Fischer M, Oberthuer A, Brors B, et al. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. *Clin Cancer Res* 2006;12 (17):5118–5128

17 Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. *J Clin Oncol* 2000;18(03):477–486

- 18 Fawzy M, El Zomor H, El Menawi S, et al. Watch and see strategy in selected neuroblastoma case scenarios: success and limitations. *J Pediatr Hematol Oncol* 2019;41(06):e384–e387
- 19 de Bouyn-Icher C, Minard-Colin V, Isapof A, Khuong Quang DA, Redon I, Hartmann O. Malignant solid tumors in neonates: a study of 71 cases [in French]. *Arch Pediatr* 2006;13(12):1486–1494
- 20 Wang Z, Sun H, Li K, et al. Prognostic factor analysis of stage 4S neuroblastoma in infant patients: a single center study. *J Pediatr Surg* 2019;54(12):2585–2588
- 21 Weintraub M, Waldman E, Koplewitz B, et al. A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly. *Pediatr Blood Cancer* 2012;59(01):182–184
- 22 Salim A, Raitio A, Mullassery D, Pizer B, Losty PD. Neuroblastoma: The Association of Anatomical Tumour Site, Molecular Biology and Patient Outcomes. *Eur J Ped Surg* 2020 (submitted)
- 23 Stokes SH, Thomas PR, Perez CA, Vietti TJ. Stage IV-S neuroblastoma. Results with definitive therapy. *Cancer* 1984;53(10):2083–2086